Roberto De Ponti
3B FUTURE Health Ventures
Monte-Carlo, Monaco
Overview
Work Experience
Board Observer
2023 - Current
Geneos Therapeutics is a developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment.
Raised $49,500,000.00 from Shanghai Healthcare Capital, 3B Future Health Fund, Global Bio Fund, Flerie Invest, Sante Ventures, Korea Investment Partners, Inovio Pharmaceuticals, Sante Ventures, Inovio Pharmaceuticals and Korea Investment Partners.
Board Observer
2022
Managing Director and General Partner
2022
Board Observer
2020
Advisor
2020
Board Member
2016
Board Member
2018 - 2023
Fore Biotherapeutics is a precision oncology company specializing in cancer therapies guided by functional genomics.
Raised $166,500,000.00 from Novartis Venture Fund, Wellington Management, SR One, OrbiMed, HBM Partners, 3B Future Health Fund, Medicxi, Samsung Securities and Cormorant Asset Management.
Board Member
2020 - 2022
Head, Corporate New Ventures and Strategic Investments
2016 - 2021
Head, Corporate Business Development
2008 - 2015
Board Observer
2017 - 2021
Aadi Bioscience develops a potentially mTOR inhibitor for targeted patient populations in oncology and cardiovascular diseases.
Raised $250,499,876.00 from KVP Capital, Alerce Medical Technology Partners, Acorn Capital Advisors, Acuta Capital Partners, Avoro Capital Advisors, Acorn Bioventures, Alta Bioequities, Rock Springs Capital, Vivo Capital and RTW Investments.